mProX™ Human S1PR4 Stable Cell Line

Skoug C, et al. "Density of Sphingosine-1-Phosphate Receptors Is Altered in Cortical ." Neurochemical research, 2023.
The present study aimed to investigate the potential alterations in Sphingosine-1-phosphate (S1P) signaling within cortical synapses of insulin-resistant Goto-Kakizaki (GK) rats and mice fed a high-fat diet (HFD). S1P is a phosphosphingolipid with diverse biological functions, acting as an intracellular second messenger and extracellular ligand to five G-protein coupled receptors (S1PR1-5). Our previous research has shown the presence of S1PRs in nerve terminals and their involvement in neuromodulation. Due to the known synaptic dysfunction in type 2 diabetes (T2D), it was hypothesized that there may be modifications in S1P signaling in these models. The study assessed the S1PR density in cortical synaptosomes from GK rats and Wistar controls, as well as HFD and low-fat-fed mice. Results indicated a lower density of S1PR1, S1PR2, and S1PR4 in nerve terminal-enriched membranes of GK rats compared to controls, despite similar cortical S1P concentrations and higher plasma S1P levels in GK rats. Similarly, HFD-fed mice exhibited increased plasma and cortical S1P concentrations, along with decreased S1PR1 and S1PR4 density. These findings suggest a possible role of S1P signaling in T2D-associated synaptic dysfunction.
Pubmed: 37794263   DOI: 10.1007/s11064-023-04033-4

Huang C, et al. "Identification of S1PR4 as an immune modulator for favorable prognosis in HNSCC ." iScience, 2023.
The largest family of membrane proteins, G protein-coupled receptors (GPCRs), play a critical role as pharmacological targets. An improved understanding of GPCRs' involvement in the tumor microenvironment may offer new perspectives for cancer therapy. In this study, machine learning was used to classify head and neck squamous cell carcinoma (HNSCC) patients into two subtypes based on GPCR expression. These subtypes showed notable differences in prognosis, gene expression, and immune microenvironment, particularly in terms of CD8(+) T cell infiltration. S1PR4 was identified as a key regulator, positively correlated with CD8(+) T cell proportion and cytotoxicity in HNSCC. It was predominantly expressed in CX3CR1(+)CD8(+) T cells among T cells. Increased expression of S1PR4 was found to enhance T cell function during CAR-T cell therapy, highlighting its potential in cancer immunotherapy. These findings identify S1PR4 as an immune modulator associated with favorable prognosis in HNSCC, suggesting its potential as a targeted therapeutic option for HNSCC treatment.
Pubmed: 37680482   DOI: 10.1016/j.isci.2023.107693